CN14 - Quality of the abeona health app according to the onco-haematology patient in the Principality of Andorra: Preliminary results

Background

This study is part of the implementation of m-Health in outpatient Clinical Pharmacy at Hospital of the Principality of Andorra, with the aim of knowing the qualification of the Abeona Health App by the patient when using it for three months. The main objectives are: 1. Determine the general rating of the App according to the patient. 2 and 3. Know if the patient would continue using the App for one year and if they would recommend the App.

Methods

Cross-sectional study in onco-haematological patients under treatment with OAAs. 1. Inclusion criteria: all adult patients treated with OAAs seen from November 2022 to May 2023 (6 months of study). 2. Tool measure: the validated spanish translation of uMars survey was chosen to meet the research objectives. 3. Data collected from the patients: age, sex, type of tumour and type of OAAs. 4. Data collected from the surveys: the uMARS questions that were used to evaluate the Abeona Health App were: 2.4, 5, 6, 7, 8, 9, 10, 11, 12, 17, 18, and 20. 5. Statistical analysis: descriptive, performed with the Jamovi statistical package. 6. Ethical aspects: before providing the surveys, the patients were informed that their data would be treated anonymously, and they gave their signed informed consent to participate.

Results

64 patients were visited. 44 participated in the study (4 of them through their children for not knowing how to use an App). 41 were women (64%) and 23 men (36%) with a mean age of 63 years. The most frequent tumor in women was the breast with OAAs Palbocilic and in men the Colon with Capecitabine. The general quality of the App according to the patient's response in the uMars survey was: 7.7% of the patients scored 3, 50% scored 4 and 42.3% scored 5. When referring to the use of the App for a year, 19.2% of the patients responded from 3 to 10 times, 46.2% from 10 to 50 times, and 34.6% more than 50 times. In relation to whether patients would recommend the App, 30.8% of the patients answered that they would recommend it to many people and 69.2% that they would recommend it to everyone.

Conclusions

1. The Abeona Health App was rated with a score of more than 4 for 92.3% of patients. 2. The 80.8% of patients would continue using it for a year. 3. The 100% of patients would recommend it to people who could benefit from it.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.